Dysregulation of GPCR signaling pathways, manifesting through aberrant ligand interactions, receptor desensitization, or imbalanced downstream effector cascades, forms the pathophysiological basis for skeletal disorders such as osteoporosis, rheumatoid arthritis, and osteogenesis imperfecta. Here, GPRC6A is linked to osteoporosis.